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of colonies formed from the interfol-
licular epidermis dropped dramatically. 
In the neonatal period and in adults, 
the greatest number of colony-forming 
units arose from cells isolated from the 
hair follicle, including the bulge area. 
Intriguingly, this shift in proliferative 
potential from the embryonic epider-
mis to the adult bulge correlates with 
the previously reported preferential 
expression of keratin-15 in the neona-
tal and embryonic epidermis and then 
to its retreat to the hair follicle bulge 
in adults (Liu et al., 2003). Thus, K-15 
expression and K-15 promoter activity 
patterns seem to correlate with colony-
forming ability.
This work indicates that skin injury 
triggers a massive migratory and pro-
liferative response from adjacent cells 
in the epidermis and hair follicle. 
Whether the response of the follicle 
and epidermis is triggered by the same 
or different factors remains to be deter-
mined. Possibly, the cells simply sense 
the loss of their neighbors and begin 
a march toward the depleted area. 
Understanding signals influencing 
recruitment of keratinocytes from epi-
dermis and follicle, as well as the sen-
sors directing cessation of proliferation 
and migration will provide new insights 
into wound repair and other cutaneous 
responses associated with malignancies 
and other disorders.
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Modeling Atopic Dermatitis with 
Increasingly Complex Mouse Models
Tiffany C. Scharschmidt1 and Julia A. Segre2
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder that 
affects approximately 15% of children in the United States. A complex disor-
der, AD is characterized by both skin barrier impairment and immunologic 
abnormalities, including decreased innate immune function and a polarized 
adaptive immune response. Mouse models have demonstrated the complex inter-
dependence of immune cell–keratinocyte interactions and teased apart gene– 
environment relationships in a controlled setting. In this issue, Nagelkerken et 
al. present a mouse model with transgenic expression of apolipoprotein C1 that 
disrupts the skin lipid barrier and manifests many hallmark features of AD.
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Atopic dermatitis (AD) is characterized 
by an erythematous and intensely pru-
ritic rash. It is popularly referred to by 
the common term “eczema,” derived 
from the Greek eczeo, meaning “to boil 
over or effervesce,” because of its ten-
dency to form epidermal microvesicles 
through a pathologic process known 
as spongiosis. The condition typically 
manifests during the first year of life, 
with progression from an extensor to a 
flexural distribution later in childhood. 
AD resolves in about 70% of cases 
by the age of 3, but its incidence has 
increased significantly over the past 
few decades. Medical management 
of AD is associated with $1 billion in 
annual direct costs in the United States, 
as well as significant indirect costs and 
emotional burden in affected families 
(Bickers et al., 2006). More than half of 
children with moderate to severe AD 
progress to develop allergic rhinitis (hay 
fever) or asthma.
AD is characterized by both skin 
barrier impairment and immunologic 
abnormalities, including decreased 
innate immune function and a polar-
ized type 2 helper T-cell (Th2)-domi-
nant immune response, which is more 
predominant in the early stage of the 
disease. Although increased serum IgE 
levels and specific Th2 cytokines have 
been found to correlate directly with 
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AD severity, it has yet to be established 
whether these immune alterations repre-
sent the primary cause of AD or a sec-
ondary response to barrier impairment. 
The skin barrier, which is formed in the 
exterior layers of the epidermis, is com-
posed of cornified envelopes—enucle-
ated keratinocytes—held together by a 
lipid matrix. Compromising the integrity 
of either of these barrier components 
could potentially lead to increased entry 
across the skin surface of allergens, irri-
tants, microbes, or toxins, with subse-
quent activation of cutaneous immune 
responses. This long-proposed theory of 
an “outside-to-inside” pathogenesis of 
AD recently gained broader acceptance 
with the discovery that mutations in the 
gene encoding a skin barrier protein, fil-
aggrin, are a major factor underlying AD 
susceptibility (Elias and Feingold, 2001; 
Sandilands et al., 2007).
In this commentary, we examine the 
salient clinical features of AD and ask 
whether they can be modeled success-
fully in mice. This leads to an inquiry 
into the role of epicutaneous sensiti-
zation and how this phenomenon can 
inform gene–environment interactions. 
Finally, we challenge the community 
to use mouse models to ask basic ques-
tions that have been difficult to address 
in patients, for example:
• What pathophysiology underlies 
the typical physical distribution of 
AD?
• Why do patients frequently clear 
their dermatitis but progress along 
an “atopic march” to asthma or 
hay fever?
• Why does barrier-impaired 
AD skin mount an insufﬁcient 
innate immune response but an 
exaggerated Th2 response?
• What are the primary defect(s) in 
AD and how can more effective 
therapeutics against AD be 
targeted?
One puzzling feature of atopic 
patients is their robust Th2 response 
to commonly encountered environ-
mental antigens (Figure 1). Animal 
models have been used successfully 
to study both environmental triggers 
and the underlying immune pathways 
that regulate this polarized response. 
Experiments involving allergen chal-
lenge have yielded a major mecha-
nistic insight pertaining to the atopic 
march, namely, that epicutaneous 
(i.e., through the skin) sensitization 
is a potent vehicle for systemic Th2 
sensitization that can readily progress 
to allergic airway hyperresponsivity. 
Epicutaneous sensitization models 
have traditionally utilized chicken-egg 
albumin—ovalbumin—as a protein 
allergen because of the many immu-
nologic resources available for char-
acterizing the specific type of immune 
response elicited. Hapten-induced AD 
models typically use trinitrochloro-
benzene to elicit certain clinical and 
immunologic features of human AD. 
A recent publication from Elias’s group 
presented a new model in which topi-
cal treatment with the hapten oxazo-
lone generated both the immunologic 
and the structural/functional epider-
mal features of AD (Man et al., 2008).
NC/NgA mice, which remain der-
matitis-free in specific pathogen-free 
conditions but develop a spontane-
ous AD-like eruption when conven-
tionally housed, have historically 
been viewed as one of the best ani-
mal models of the condition. One of 
the major advantages of this model is 
the varied response to environmen-
tal factors (e.g., exposure to dust mite 
or Staphylococcus aureus antigens or 
increased psychological stress), which 
provides insight into the heterogeneity 
of AD pathophysiology. Experiments 
in NC/NgA mice have also helped to 
dissect further the role of Th1 and Th2 
cytokines and the immunopathologic 
basis of AD. Although these mice pro-
vide an advantageous model for study-
ing triggers and treatments for AD, 
their undefined genetic structure lim-
its their utility, either as a standalone 
model or via crosses with transgenic 
mice, in dissecting the role of genetic 
susceptibility (Terada et al., 2006).
To date, animal models have 
yielded informative results concerning 
the role of genes whose expression is 
correlated with but not known to be 
causative for AD in human patients. 
For example, thymic stromal lympho-
poietin (TSLP), a proinflammatory 
cytokine that activates dendritic cells 
to generate Th2 inflammatory respons-
es, is highly upregulated in the kera-
tinocytes of AD patients (Soumelis et 
al., 2002). Skin-specific (keratin (K)5 
promoter) transgenic expression of 
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Figure 1. Immune response to impaired skin barrier in atopic dermatitis.
COMMENTARY
 www.jidonline.org 1063
TSLP (K5-TSLP) results in an AD-like 
phenotype, with infiltration of Th2-
dominant CD4+ lymphocytes, mast 
cells, and eosinophils, as well as ele-
vated serum IgE (Yoo et al., 2005). To 
address the question of whether Th2 
cells are required for the development 
of these AD-like features and to deter-
mine their hierarchy in the AD inflam-
matory response, these investigators 
generated T-cell-deficient K5-TSLP 
transgenic mice, which, aside from 
normal serum IgE, demonstrate many 
features of the inflammatory skin phe-
notype. These experiments have begun 
to tease apart the roles of lympho-
cyte and myeloid lineage cells in AD. 
An important future approach would 
involve epicutaneously challeng-
ing these mice to determine whether 
T cells are necessary to proceed with 
the atopic march.
In this issue, Nagelkerken et al. 
(2008) present an exciting new animal 
model with transgenic expression of 
apolipoprotein C1 (APOC1) disrupting 
the lipid component of the skin barrier 
and resulting in a mouse with many 
of the clinical features of atopic der-
matitis. (Table 1). The model displays 
both gross and histologic features of 
AD, including pruritus and spongio-
sis, respectively, which are hallmark 
features of the condition in humans. 
Importantly, this model also responds 
to topical treatment with corticoste-
roids, suggesting its potential utility for 
studying the efficacy of novel thera-
pies. Finally, the work with APOC1 
transgenic mice not only suggests that 
components of the lipid metabolism 
pathway are good candidates for iden-
tifying additional AD-susceptibility 
genes but also represents an opportu-
nity to manage and perhaps even pre-
vent subsequent atopic disorders with 
barrier restoration.
Animal models have demonstrated 
how gene–environment and immune 
cell–keratinocyte interactions can 
be studied in controlled settings. 
Experiments with human cells and 
reconstructed human epidermis have 
also contributed greatly to our under-
standing of these complex relation-
ships, with many new models having 
been published recently. These mod-
els have collectively challenged prior 
hypotheses about the role of barrier 
function and inflammation in AD. The 
lipid and protein components of the 
stratum corneum have often been con-
sidered independent modulators of 
barrier function. However, recent char-
acterization of mice deficient in 12R-
lipoxygenase, which converts arachi-
donic acid to barrier lipid components, 
revealed not only defects in ceramide 
composition but also increased corni-
fied envelope fragility and impaired 
filaggrin processing (Epp et al., 2007). 
Animal and in vitro models have also 
been used to re-examine the relation-
ship between barrier function and the 
innate and adaptive immune response. 
For example, mice deficient in the 
antimicrobial peptide CRAMP demon-
strate impaired barrier function (Aberg 
et al., 2007), and human keratinocytes 
were shown to express lower levels of 
filaggrin when differentiated with the 
Th2 cytokines interleukin 4 and inter-
leukin 13 vs. interferon-γ (Howell et 
al., 2007). The latter results are intrigu-
ing because they suggest that filaggrin 
deficiency in AD patients may result 
from a combination of genetic muta-
tions and Th2 polarization (Figure 1).
To date, animal models for AD 
have provided great insight into the 
disease, but they have also generated 
many new questions. Topics to be 
addressed include the effect of under-
lying genetic variation, the relation-
ship between the skin barrier and the 
innate and adaptive immunity, and the 
role of epicutaneous sensitization by 
environmental allergens. A reproduc-
ible, accessible, and relevant animal 
model of AD would be immensely 
valuable for all these investigations. 
However, the complexity and vari-
ability of AD as a clinical entity make 
creating such a model particularly 
challenging. Because there are mul-
tiple genetic and environmental fac-
tors underlying AD, the notion of 
developing a single comprehensive 
animal model is unrealistic. However, 
many of these disease components 
can be modeled both alone and in 
combination to address questions of 
pathophysiology and treatment. When 
working in another biologic system 
we must be aware that not all fac-
tors, either genetic or environmental, 
will necessarily have the same effect 
on mice that they do in humans; con-
versely, we must remain open to fortu-
itous surprises such as mouse models 
that unexpectedly manifest AD-like 
features, lending new insight into pos-
sible human genetic predisposition.
Given these caveats, we challenge 
ourselves and the scientific community 
to develop clinically relevant animal 
models that take their cue from obser-
vations in human disease. For example, 
it will be fascinating to examine the 
extent to which mice with a targeted 
deletion of filaggrin are predisposed to 
developing AD-like features. Although 
the flaky tail mouse has defects in filag-
grin processing, the underlying genetic 
defect has not yet been determined 
(Presland et al., 2000). Our ability to 
model genetic predisposition to AD in 
mice will allow us to understand how 
selective skin barrier impairment mod-
ulates adaptive and innate immune 
responses, discover how AD initiates 
atopic progression, and, finally, test 
novel therapies.
|This mouse model of atopic dermatitis underscores the 
cutaneous barrier.
Table 1. Salient clinical features of AD modeled in APOC1 transgenic 
animals
Gross morphology Scaling, licheniﬁcation, excoriations, and pruritus
Histology Acanthosis and spongiosis, immune-cell inﬁltration (CD4+ T cells,  
eosinophils, mast cells, and macrophages)
Antibody titers Increased serum IgE parallels disease progression
Treatment Corticosteroids suppress development of AD-like phenotype
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T-Helper 17 Cells in Psoriatic Plaques 
and Additional Genetic Links 
between IL-23 and Psoriasis
Andrew Blauvelt1,2
T-helper 17 (Th17) cells are a newly appreciated T-cell subset, distinct from both 
Th1 and Th2 cells, that have been implicated in the pathogenesis of psoriasis and 
other autoimmune inflammatory diseases (Figure 1) (Fitch et al., 2007; Kastelein 
et al., 2007). IL-23 stimulates survival and proliferation of Th17 cells and thus 
serves as a key master cytokine regulator for these diseases. 
Journal of Investigative Dermatology (2008), 128, 1064–1067. doi:10.1038/jid.2008.85
In psoriasis lesions, IL-23 is overpro-
duced by dendritic cells (Lee et al., 
2004; Wilson et al., 2007) and kerati-
nocytes (Piskin et al., 2006), and this 
cytokine stimulates Th17 cells within 
dermis to make “Th17 cytokines,” 
which include IL-17A, IL-17F, tumor 
necrosis factor (TNF)-α, IL-21, and IL-
22 (Figure 1) (Fitch et al, 2007; Kastelein 
et al, 2007). IL-22—rather than IL-17A, 
for which Th17 cells are named—is 
emerging as the prototypic Th17 cyto-
kine that is perhaps most specific for 
Th17 cells (Liang et al., 2006). Because 
it is a potent stimulus for keratinocyte 
proliferation (Wolk et al., 2006; Sa et 
al., 2007; Zheng et al., 2007), IL-22 has 
also gained prominence in the patho-
genesis of psoriasis as a key effector 
Th17 cytokine (Fitch et al., 2007).
In this issue, Krueger and his group of 
investigators at Rockefeller University 
show for the first time the discrete pres-
ence of IL-17A-producing cells within 
the dermis of psoriatic plaques (Lowes 
et al., 2008). Previously, Krueger’s and 
other groups had found increased lev-
els of mRNA specific for the T-helper 
17 (Th17) cytokines mentioned above, 
as well as increased mRNA levels for 
the IL-23 subunits, IL-12/23p40 and 
IL-23p19, in psoriasis (Lee et al., 2004; 
Chan et al., 2006; Wilson et al., 2007). 
To demonstrate IL-17A+ cells within 
psoriatic plaques, skin was biopsied, 
epidermis was separated from dermis 
using dispase, and leukocytes were 
allowed to spontaneously “crawl-out” 
of dermis placed into culture. These 
cells were then collected; stimulated 
for 4 hours with phorbol ester and 
ionomycin; labeled with antibodies 
directed against IL-17A, IFN-γ, and 
TNF-α; and analyzed by flow cytome-
try. Psoriasis plaque dermis contained a 
mean of 6.2% of cells secreting IL-17A, 
whereas dermis from normal-appearing 
skin contained a mean of 0.5% of cells 
making IL-17A. Dermal cells co-secret-
ing IL-17A and TNF-α (5.1%) and der-
mal cells co-secreting IL-17A and IFN-γ 
(1.9%) were also significantly elevated 
in psoriasis as compared with normal-
appearing skin (0.2 and 0.1%, respec-
tively). The level of cells producing 
IFN-γ alone was statistically not higher 
in psoriatic dermis when compared 
with normal dermis. Taken together, 
these results suggest that there is a 
greater propensity for IL-17A-produc-
ing cells, rather than IFN-γ-producing 
cells, to be present in psoriatic plaques 
when compared to healthy skin. In a 
quantifiable manner, Th17 cytokine 
mRNA data in psoriatic plaques have 
now been linked with actual numbers 
of cells producing these cytokines with-
in diseased tissue.
One caveat of this work is that it has 
become clear that IL-17A production 
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